2023year6month29 - 30On the day, the 9th China Biomedical Innovation Cooperation ConferenceBIO-PHARM 2023) and Hua Medicine Ranking2023The China Biopharmaceutical Industry Value List Awards Ceremony was held at the Kempinski Hotel in Suzhou Jinji Lake. Huayi Research Institute has selected and discovered innovative enterprises in the biomedical field that truly have industry influence and growth potential, and is dedicated to creating the Huayi List.2023China's Biomedical Industry Value List aims to promote industrial innovation and development.
Hua Medicine Ranking2023The China Biopharmaceutical Industry Value List includes antibody drugs, innovative therapies, biotechnology,CRO company,CDMO companyThe selection of six series of pharmaceutical innovation partners is based on the enterprise quantitative growth evaluation criteria refined over many years by the Huayi Research Institute. It combines basic processes such as questionnaire surveys, corporate interviews, data analysis, and verification. The evaluation panel standardizes and quantifies the dynamic data of shortlisted enterprises through processing, thereby selecting the companies with significant industry value for the year and forming an objective third-party evaluation list in the industry.
Frost & SullivanFrost & SullivanFrost & Sullivan, the abbreviation for 'Frost & Sullivan' Evaluation of Pharmaceutical R&D Partnerships, aims to recognize companies that have made outstanding contributions and performed excellently in the field of biomedicine.
Frost & Sullivan integrates globally.62years of consulting experience,25Over the years, we have wholeheartedly served the booming Chinese market, using a global perspective to help clients accelerate their business growth and achieve benchmark positions in industry growth, innovation, and leadership. The Greater Health Industry is one of the core areas of focus for Frost & Sullivan's research.
The Healthcare Business Unit of Frost & Sullivan has professional analytical capabilities and rich project experience in the life sciences field. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, the Healthcare Business Unit has unique core advantages in healthcare industry investment and financing services.
Frost & Sullivan's Healthcare practice has a wide base of corporate clients in China, and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated. Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions, offering one-stop solutions in specialized fields such as pharmaceuticals and medical devices. Our services have received widespread attention from investors.
As one of the important service institutions for Hong Kong-listed companies, industry consultants play a crucial role in the successful listing and financing of enterprises in the biotechnology sector, which has a high technical threshold. As an industry consultant, Frost & Sullivan is deeply involved in both early-stage investment and post-listing activities in the healthcare sector, making it the top choice for healthcare companies seeking to list in Hong Kong. According to the information disclosed by the Hong Kong Exchanges,2015till2022In FY, Frost & Sullivan went on to maintain its market-leading position in the Hong Kong-listed consultancy segment for consecutive years.8Maintaining a leading position year after year, we have helped the majority of listed companies in the market to remain at the top in their respective segments. We are an absolute leader in serving healthcare companies seeking to go public in Hong Kong.
2019yearASince the launch of the Sci-tech Innovation Board, Frost & Sullivan's share has reached72.3%In addition, due to the high demand for business and industry analysis in the fifth set of issues, industry advisory services were systematically adopted. Frost & Sullivan's share of clients served under the fifth set of standards has reached83.8%(Number of projects).
since2018Since the beginning of this year, Frost & Sullivan has successively released "TheECMO unitIndustry Status quo and Development Trend Report , "China Rare Disease Industry Trend Observation Report", Medical DevicesCRO companyIndustry Status quo and Development Trends Report "Report on the Current Situation and Development Trends of the Improved New Drug Industry", "Research Report on the Current Development Status and Future Trends of the Ophthalmic Drug Market", "White Paper on the Current Industry Situation and Future Development of China's Assisted Reproduction Industry", Medical Intelligence Industry White Paper We have contributed to the research and promotion of various sub-industries through multiple white papers, providing important reference perspectives for market investors.
2022year9In January, the first New Investment Expo and the 16th Frost & Sullivan Global Growth, Innovation and Leadership Summit BioTech Investment Forum were successfully held in Shanghai. At the event, the Frost & Sullivan Growth, Innovation and Leadership Awards in the biotech sector were announced, along with the official release ofCDMO companyIndustry Current Situation and Development Trend Research Report". Numerous biotech companies, investment institutions, and professional service providers gathered at the event to focus on new trends in biotech investment and financing, participating in the forum on-site.180+People, watching online2,000+person.
2023year9month28On the 1st, the 2nd New Investment Expo and the 17th Frost & Sullivan Global Growth, Innovation and Leadership Summit Biotechnology Investment Forum will be held again in Shanghai. Frost & Sullivan will continue to leverage its industrial value by building a professional cooperation platform through this forum, stimulating innovation vitality in the biotechnology industry, promoting investment and financing cooperation and resource sharing, and jointly advancing the sustainable development of the pharmaceutical innovation industry with industry partners.
The registration channel for the conference has been officially opened.
Scan the QR code to register for the event
Frost & Sullivan is considered one of the most powerful, professional, and influential industry research institutions in the sector. We aim to work with more biotech companies to gain insights into industry trends, seize development opportunities, jointly promote innovation and upgrading of China's large health industry, and create a healthy future.
